News

APX001 has received orphan drug designation for four distinct indications: the treatment of invasive candidiasis, invasive aspergillosis, coccidioidomycosis, and rare mold infections caused by Scedosporium spp., Fusarium spp.,

har Pharmaceuticals focused on transforming IV-only drugs into oral drugs for existing and new indications using its proprietary technology EnhanceTM development platform. With this acquisition, Grünenthal has obtained

Virttu, based in Glasgow, Scotland, is a privately-held biopharmaceutical company focused on the development of oncolytic virus therapy for treatment of cancer. Virttu's lead product candidate Seprehvir (HSV1716) is

Ezutromid dosing is expected to follow within a screening period of up to 28 days.  Enrolment and dosing of patients into PhaseOut DMD in the UK is ongoing.

In the global phase 3, multicenter, randomized 24-week, double-blind, placebo-controlled Strive study, 955 patients were randomized to receive once-monthly subcutaneous placebo or erenumab (70 mg or 140 mg)

Marinus is developing ganaxolone IV for the treatment of status epilepticus, a life-threatening medical emergency associated with high mortality and limited treatment options. The data was presented during

The trial, Expedition-4, enrolled 104 patients including 85 who were receiving dialysis at enrollment, 20 with compensated cirrhosis and 44 who were not cured with sofosbuvir with ribavirin

Braeburn Pharmaceuticals and Camurus announced the positive top-line results from the pivotal phase 3 randomized, double-blind, double-dummy, active controlled trial of weekly and monthly injections of buprenorphine. Apart

Enrollment in the 60-patient open label Phase 3 trial is ongoing across multiple sites in the United States, trial completion is expected in the first half of 2017,